Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hunan Province Tumor Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1)≥18;
2\) advanced non-small cell lung cancer confirmed by histopathology;
3\) Patients with NSCLC who have previously or are taking gefitinib (first-line therapy) or osimertinib (post-TKI resistance) or crizotinib monotherapy, and the response to treatment can be assessed;
4\) Have sufficient FFPE tissue samples within 5 years: 5 large specimens/case; There were 10 puncture specimens/case
You may not be if
1\) Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs;
2)Maintenance therapy if the disease does not progress after treatment with other antitumor methods
Clareo Health | To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC
